Clinical Trial

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

Name: The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease — clinical trial record (NCT07028632)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-06-11.

Trial Details

NCT Number	NCT07028632
Lead Sponsor	iRegene Therapeutics Co., Ltd.
Conditions	Parkinson Disease (PD)
Enrollment	30 participants
Start Date	2025-06-30
Primary Completion	2026-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-06-29